IceCure Medical

Focus: IceCure Medical is a medical device biotechnology company specializing in cryoablation technology for minimally invasive treatment of cancerous tumors and benign lesions. Based in Israel with a focused pipeline across oncology and gynecology indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About IceCure Medical

AI assessmentNot Hiring

No open roles listed right now. Follow IceCure Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Ice-Sense3TM/ ProSenseTM

Breast Cancer

N/A

Clinical Trials (1)

NCT02200705Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial

N/A

Help build intelligence for IceCure Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Emerging innovator in cryoablation with potential to establish new standard of care across multiple tumor types (breast, renal, uterine)
Early-stage company offers opportunity for significant individual impact and career growth as clinical and regulatory milestones are achieved
Diversified pipeline addressing oncology and benign indications suggests multiple expansion pathways

Watch Out For

No commercial revenue, manufacturing partnerships, or FDA approvals documented—execution risk is high
Zero active job openings and minimal public hiring activity suggest limited near-term headcount expansion opportunities
Missing critical data on funding, employee count, and financial runway creates visibility gap on company stability

Generated by Claude from IceCure Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PROSENSE™

Renal Cell Carcinoma

N/A

Clinical Trials (1)

NCT02399124Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

N/A

Cryoablation

Breast Cancer

N/A

Clinical Trials (1)

NCT06300125Percutaneous Cryoablation of Low-risk Early Breast Cancer

N/A